The Clinical Significance of Follow Up SCC Levels in Patients with Recurrent Squamous Cell Carcinoma of the Cervix.
- Author:
Young Min CHOI
1
;
Sung Kwang PARK
;
Heung Lae CHO
;
Kyoung Bok LEE
;
Ki Tae KIM
;
Juree KIM
;
Seung Chang SOHN
Author Information
1. Department of Radiation Oncology, Pusan Paik Hospital, Busan, Korea.
- Publication Type:Original Article
- Keywords:
SCC antigen;
Cervix cancer;
Recurrence
- MeSH:
Carcinoma, Squamous Cell*;
Cervix Uteri*;
Diagnosis;
Female;
Follow-Up Studies*;
Humans;
Immunoassay;
Radiotherapy;
Recurrence;
Reference Values;
Uterine Cervical Neoplasms
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2002;20(4):353-358
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the clinical usefulness of a follow-up examination using serum squamous cell carcinoma antigen (SCC) for the early detection of recurrence in patients treated for cervical squamous cell carcinoma. MATERIALS AND METHODS: 20 patients who were treated for recurrent cervical squamous cell carcinoma between 1997 and 1998, who had experienced a complete remission after radiotherapy and who underwent an SCC test around the time when recurrence was detected, were included in this study. The levels of SCC were measured from the serum of the patients by immunoassay and values less than 2 ng/mL were regarded as normal. The sensitivity of the SCC test for use in the detection of recurrence, the association between the SCC values and the recurrence patterns and the tumor size and stage, and the temporal relation between the SCC increment and recurrence detection were evaluated. RESULTS: The SCC values were above normal in 17 out of 20 patients, so the sensitivity of the SCC test for the detection of recurrence was 85%, and the mean and median of the SCC values were 15.2 and 9.5 ng/mL, respectively. No differences were observed in the SCC values according to the recurrence sites. For 11 patients, the SCC values were measured over a period of 6 months before recurrence was detected, and the mean and median values were 13.6 and 3.6 ng/mL, respectively. The SCC values of 7 patients were higher than the normal range, and the SCC values of the other 4 patients were normal but 3 among them were above 1.5 ng/mL. At the time of diagnosis, the SCC valuess were measured for 16 of the 20 recurrent patients, and the SCC values of the patients with a bulky tumor (> or =4 cm) or who were in stage IIb or III were higher than those of the patients with a non-bulky tumor or who were in stage Ib or IIa. CONCLUSION: The SCC test is thought to be useful for the early detection of recurrence during the follow up period in patients treated for cervical squamous cell carcinoma. When an effective salvage treatment is developed in the future, the benefit of this follow-up SCC test will be increased.
